Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MW05 is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate developed by Moonwalk Biosciences. It is specifically designed to address metabolic conditions by modulating the endocrine function of adipose tissue, leading to a lipid-lowering effect. As part of Moonwalk's broader portfolio of epigenetic and RNA-based therapies, MW05 aims to leverage the company's expertise in genomic signaling to restore healthy metabolic states. The program is currently in the preclinical phase of development and is part of a pipeline that includes other adipose-targeted candidates such as MW01, MW02, and MW03.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MW05.